Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | PTPRB | P23467 | 9/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4209295 | 1.00 | ABCB1 (0.48) | ABCB1KMT2ATSHRHSD17B10PTPRB | |
| SCHEMBL31146240 | 0.84 | ABCB1 (0.45) | ABCB1KMT2ATSHRHSD17B10PTPRB | |
| SCHEMBL14019980 | 0.83 | ABCB1 (0.52) | ABCB1KMT2ATSHRHSD17B10PTPRB | |
| SCHEMBL22154278 | 0.83 | ABCB1 (0.52) | ABCB1KMT2ATSHRHSD17B10PTPRB | |
| SCHEMBL20532824 | 0.82 | ABCB1 (0.56) | ABCB1KMT2ATSHRHSD17B10PTPRB | |
| SCHEMBL31146181 | 0.81 | ABCB1 (0.44) | ABCB1KMT2ATSHRHSD17B10PTPRB | |
| SCHEMBL1058980 | 0.81 | ABCB1 (0.73) | ABCB1KMT2APTPRB | |
| SCHEMBL27595388 | 0.81 | ABCB1 (0.73) | ABCB1KMT2APTPRB | |
| SCHEMBL13535505 | 0.81 | ABCB1 (0.73) | ABCB1KMT2APTPRB | |
| SCHEMBL2840468 | 0.80 | RAB9A (0.44) | KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012054510-A1 | OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-8143251-B2 | Triazolotriazines as kinase inhibitors | INCYTE CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110144113-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2011-06-16 | — | — | US | disclosed |
| US-7915408-B2 | Triazolotriazines as kinase inhibitors | INCYTE CORPORATION (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915408-B2 | Triazolotriazines as kinase inhibitors | INCYTE CORPORATION (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100130467-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2010-05-27 | — | — | US | disclosed |
| US-20100130467-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2010-05-27 | — | — | US | disclosed |
| US-7683060-B2 | Triazolotriazines as kinase inhibitors | INCYTE CORPORATION (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683060-B2 | Triazolotriazines as kinase inhibitors | INCYTE CORPORATION (US) | 2010-03-23 | — | — | US | disclosed |
| WO-2008021781-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | MET, ERBB2, RET | ABCB1 756/4885KMT2A 403/4885TSHR 1101/4885 |
| US-20100130467-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | MET, ERBB2, RET | ABCB1 756/4885KMT2A 403/4885TSHR 1101/4885 |
| US-20110144113-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | MET, ERBB2, RET | ABCB1 756/4885KMT2A 403/4885TSHR 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.